Geron (NASDAQ:GERN) Stock Rating Lowered by B. Riley

B. Riley cut shares of Geron (NASDAQ:GERN) from a buy rating to a neutral rating in a research report sent to investors on Thursday morning, Marketbeat Ratings reports. The firm currently has $2.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $3.50. B. Riley also issued estimates for Geron’s Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS and Q4 2025 earnings at ($0.02) EPS.

Several other research analysts also recently issued reports on GERN. Barclays reiterated an “overweight” rating and set a $4.00 price target (down from $9.00) on shares of Geron in a report on Thursday. HC Wainwright downgraded shares of Geron from a “buy” rating to a “neutral” rating in a report on Wednesday. Finally, Needham & Company LLC increased their price objective on Geron from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $5.68.

Geron Stock Up 1.1 %

Shares of NASDAQ:GERN opened at $1.76 on Thursday. The company has a fifty day moving average of $2.93 and a 200-day moving average of $3.77. The company has a market capitalization of $1.06 billion, a PE ratio of -5.50 and a beta of 0.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. Geron has a 52-week low of $1.46 and a 52-week high of $5.34.

Geron (NASDAQ:GERN) last announced its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). The company had revenue of $47.54 million during the quarter, compared to the consensus estimate of $45.29 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. On average, equities analysts predict that Geron will post -0.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in GERN. Creative Planning raised its position in shares of Geron by 23.8% in the 3rd quarter. Creative Planning now owns 92,784 shares of the biopharmaceutical company’s stock worth $421,000 after acquiring an additional 17,837 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Geron by 23.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 4,094 shares in the last quarter. abrdn plc bought a new position in shares of Geron in the 3rd quarter worth about $6,752,000. US Bancorp DE grew its stake in shares of Geron by 68.4% in the 3rd quarter. US Bancorp DE now owns 18,296 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 7,429 shares during the period. Finally, Rovin Capital UT ADV acquired a new stake in shares of Geron in the 3rd quarter valued at about $62,000. 73.71% of the stock is owned by institutional investors.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.